Lipella Pharmaceuticals Future Growth
Future criteria checks 2/6
Lipella Pharmaceuticals is forecast to grow earnings and revenue by 3.3% and 94.8% per annum respectively while EPS is expected to grow by 17.8% per annum.
Key information
3.3%
Earnings growth rate
17.8%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 94.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -13 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -8 | N/A | N/A | 1 |
| 12/31/2024 | 0 | -5 | N/A | N/A | 1 |
| 9/30/2024 | 0 | -4 | -4 | -4 | N/A |
| 6/30/2024 | 1 | -4 | -4 | -4 | N/A |
| 3/31/2024 | 0 | -5 | -3 | -3 | N/A |
| 12/31/2023 | 0 | -5 | -3 | -3 | N/A |
| 9/30/2023 | 0 | -4 | -3 | -3 | N/A |
| 6/30/2023 | 0 | -4 | -2 | -2 | N/A |
| 3/31/2023 | 0 | -3 | -2 | -2 | N/A |
| 12/31/2022 | 0 | -3 | -2 | -2 | N/A |
| 9/30/2022 | 0 | -3 | -2 | -2 | N/A |
| 6/30/2022 | 0 | -2 | -2 | -2 | N/A |
| 3/31/2022 | 0 | -2 | -2 | -2 | N/A |
| 12/31/2021 | 0 | -2 | -1 | -1 | N/A |
| 12/31/2020 | 1 | 0 | 0 | 0 | N/A |
| 12/31/2019 | 1 | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LIPO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LIPO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LIPO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LIPO's revenue (94.8% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: LIPO's revenue (94.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LIPO's Return on Equity is forecast to be high in 3 years time